{"protocolSection": {"identificationModule": {"nctId": "NCT00939341", "orgStudyIdInfo": {"id": "D5890L00035"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia", "officialTitle": "Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy (SMART) in Asthma Patients Across Asia: SMARTASIA", "acronym": "SMARTASIA"}, "statusModule": {"statusVerifiedDate": "2012-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-07"}, "primaryCompletionDateStruct": {"date": "2010-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-07-13", "studyFirstSubmitQcDate": "2009-07-14", "studyFirstPostDateStruct": {"date": "2009-07-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-08-11", "resultsFirstSubmitQcDate": "2011-10-20", "resultsFirstPostDateStruct": {"date": "2011-11-28", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-01-12", "lastUpdatePostDateStruct": {"date": "2012-01-16", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to compare whether Symbicort Maintenance \\& Reliever Therapy (SMART) is more effective in uncontrolled asthmatic patients than their current therapy in a real life situation."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Symbicort SMART"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 862, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Symbicort Turbuhaler 160/4.5 \u00b5g delivered dose", "interventionNames": ["Drug: Symbicort (Budesonide/Formoterol)"]}], "interventions": [{"type": "DRUG", "name": "Symbicort (Budesonide/Formoterol)", "description": "Turbuhaler 160/4.5 \u00b5g delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms", "armGroupLabels": ["1"], "otherNames": ["Symbicort"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Asthma Control Questionnaire (ACQ(5)) Score From Baseline at a Regional Level", "description": "Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12).", "timeFrame": "Baseline and 12 weeks"}], "secondaryOutcomes": [{"measure": "Change in ACQ(5) Score From Baseline at Country Level (China)", "description": "Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12).", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change in Overall ACQ(5) Score From Baseline at Country Level (India)", "description": "Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12).", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change in Overall ACQ(5) Score From Baseline at Country Level (Indonesia)", "description": "Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12).", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change in Overall ACQ(5) Score From Baseline at Country Level (Taiwan)", "description": "Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12).", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change in Overall ACQ(5) Score From Baseline at Country Level (Thailand)", "description": "Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12).", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change in Asthma Quality of Life Questionnaire, Standardized Version (AQLQ (S)) Overall Scores From Baseline", "description": "Participants' QOL were scored on a scale of decreasing QOL impairment from 1 to 7, in which 1 = maximum impairment. The change in overall mean AQLQ(S) score from baseline were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12)", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change in AQLQ (S) Domain (Symptom) Scores From Baseline", "description": "Participants' QOL were scored on a scale of decreasing QOL impairment from 1 to 7, in which 1 = maximum impairment. The change in overall mean AQLQ(S) symptom score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12).", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change in AQLQ (S) Domain (Activity Limitation) Scores From Baseline", "description": "Participants' QOL were scored on a scale of decreasing QOL impairment from 1 to 7, in which 1 = maximum impairment. The change in overall mean AQLQ(S) symptom score from baseline were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12)", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change in AQLQ (S) Domain (Emotion Function) Scores From Baseline", "description": "Participants' emotional functions were scored on a scale of decreasing impairment to emotional function from 1 to 7, in which 1 = maximum impairment. The change in overall mean AQLQ(S) emotion function score were calculated as change from baseline (Week 0) to the treatment period (mean of the scores at Week 4, Week 8, Week 12)", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Change in AQLQ (S) Domain (Environmental Stimuli) Scores From Baseline", "description": "Participants ' responses to environmental stimuli were scored on a scale of decreasing response to environmental stimuli from 1 to 7, in which 1 = maximum response. The change in overall mean AQLQ(S) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12)", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Study Medication Use (Maintenance and Reliever) in Diary Cards - Change in As-needed Day-time Reliever Medication From run-in Period", "description": "Change in the number of as-needed day-time inhalations of medication, defined as the difference in mean value of all available data obtained during treatment period and mean value in run-in period.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Study Medication Use (Maintenance and Reliever) in Diary Cards - Change in As-needed Night-time Reliever Medication From run-in Period", "description": "Change in the number of as-needed night-time inhalations of medication, calculated as difference in mean value of all available data obtained during treatment period and mean value in run-in period.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Study Medication Use (Maintenance and Reliever) in Diary Cards - Total Number of Inhalations of Symbicort\u00ae 160\u00b5g/4.5\u00b5g Per Day During Treatment Period", "description": "Total number of inhalations of Symbicort\u00ae 160\u00b5g/4.5\u00b5g per day during treatment period, defined as the sum of maintenance medication and as-needed medication during night and day time", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Study Medication Use (Maintenance and Reliever) in Diary Cards - Percentage of Days During Treatment Period Participants Used \u2265 3 Inhalations of Symbicort\u00ae 160\u00b5g/4.5\u00b5g in a Day", "description": "The mean percentage of days during treatment period participants used \u2265 3 inhalations of Symbicort\u00ae 160\u00b5g/4.5\u00b5g in a day", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Study Medication Use (Maintenance and Reliever) in Diary Cards - Percentage of Days During Treatment Period Participants Used \u2265 5 Inhalations of of Symbicort\u00ae 160\u00b5g/4.5\u00b5g in a Day", "description": "The mean percentage of days during treatment period participants used \u2265 5 inhalations of Symbicort\u00ae 160\u00b5g/4.5\u00b5g in a day", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Study Medication Use (Maintenance and Reliever) in Diary Cards - Percentage of Days During Treatment Period Participants Used \u2265 9 Inhalations of Symbicort\u00ae 160\u00b5g/4.5\u00b5g in a Day", "description": "The mean percentage of days during treatment period participants used \u2265 9 inhalations of Symbicort\u00ae 160\u00b5g/4.5\u00b5g in a day", "timeFrame": "Baseline and 12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of signed informed consent\n* Asthma diagnosis at least 6 months before visit 1 of study\n* Patients who have reversible airway obstruction continuous asthma treatment except Symbicort at least within 4 weeks before visit 1 of study\n\nExclusion Criteria:\n\n* Known or suspected allergy to active ingredients of study medication or excipients\n* Use of oral, rectal or parenteral glucocorticosteroids 30 days before visit 1 of study\n* Smoking, current or previous with a smoking history of \u2265 10 pack years", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Guy Yeoman, MD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Guangzhou", "state": "Guangdong", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"facility": "Research Site", "city": "Zheng Ahou", "state": "He Nan", "country": "China"}, {"facility": "Research Site", "city": "Wuhan", "state": "Hubei", "country": "China", "geoPoint": {"lat": 30.58333, "lon": 114.26667}}, {"facility": "Research Site", "city": "Changsha", "state": "Hunan", "country": "China", "geoPoint": {"lat": 28.19874, "lon": 112.97087}}, {"facility": "Research Site", "city": "Qingdao", "state": "Shandong", "country": "China", "geoPoint": {"lat": 36.06488, "lon": 120.38042}}, {"facility": "Research Site", "city": "Shanghai", "state": "Shanghai", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Research Site", "city": "Beijing", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Research Site", "city": "Chengdu", "country": "China", "geoPoint": {"lat": 30.66667, "lon": 104.06667}}, {"facility": "Research Site", "city": "Fuzhou", "country": "China", "geoPoint": {"lat": 26.06139, "lon": 119.30611}}, {"facility": "Research Site", "city": "Hangzhou", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Research Site", "city": "Nanjing", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Research Site", "city": "Shenyang", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Research Site", "city": "Zhengzhou", "country": "China", "geoPoint": {"lat": 34.75778, "lon": 113.64861}}, {"facility": "Research Site", "city": "Hyderabad", "state": "Andhra Pradesh", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Research Site", "city": "Ahmedabad", "state": "Gujarat", "country": "India", "geoPoint": {"lat": 23.02579, "lon": 72.58727}}, {"facility": "Research Site", "city": "Bangalore", "state": "Karnataka", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Research Site", "city": "Bengaluru", "state": "Karnataka", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Research Site", "city": "Indore", "state": "Madhya Pradesh", "country": "India", "geoPoint": {"lat": 22.71792, "lon": 75.8333}}, {"facility": "Research Site", "city": "Mumbai", "state": "Maharashtra", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Research Site", "city": "Chennai", "state": "Tamil Nadu", "country": "India", "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"facility": "Research Site", "city": "Coimbatore", "state": "Tamil Nadu", "country": "India", "geoPoint": {"lat": 11.00555, "lon": 76.96612}}, {"facility": "Research Site", "city": "Lucknow", "state": "Uttar Pradesh", "country": "India", "geoPoint": {"lat": 26.83928, "lon": 80.92313}}, {"facility": "Research Site", "city": "Noida", "state": "Uttar Pradesh", "country": "India", "geoPoint": {"lat": 28.58, "lon": 77.33}}, {"facility": "Research Site", "city": "Jakarta", "state": "DKI Jakarta", "country": "Indonesia", "geoPoint": {"lat": -6.21462, "lon": 106.84513}}, {"facility": "Research Site", "city": "Surabaya", "state": "East Java", "country": "Indonesia", "geoPoint": {"lat": -7.24917, "lon": 112.75083}}, {"facility": "Research Site", "city": "Chia-Yi", "country": "Taiwan"}, {"facility": "Research Site", "city": "Hsin Chu", "country": "Taiwan"}, {"facility": "Research Site", "city": "Kaohsiung", "country": "Taiwan", "geoPoint": {"lat": 22.61626, "lon": 120.31333}}, {"facility": "Research Site", "city": "Taichung", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Research Site", "city": "Taipei", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Taoyuan City", "country": "Taiwan", "geoPoint": {"lat": 24.95233, "lon": 121.20193}}, {"facility": "Research Site", "city": "Pathumwan", "state": "Bangkok", "country": "Thailand"}, {"facility": "Research Site", "city": "Nakhonratchasima", "state": "Naimuang", "country": "Thailand"}, {"facility": "Research Site", "city": "Bangkok", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Research Site", "city": "Pathumthani", "country": "Thailand", "geoPoint": {"lat": 14.01346, "lon": 100.53049}}]}, "referencesModule": {"references": [{"pmid": "26831844", "type": "DERIVED", "citation": "Lin J, Tang Y, Xiu Q, Kang J, Cai S, Huang K, Itoh Y, Ling X, Zhong N. Real-life effectiveness of budesonide/formoterol therapy in asthma: A subanalysis of the SMARTASIA study. Allergy Asthma Proc. 2016 Jan-Feb;37(1):27-34. doi: 10.2500/aap.2016.37.3910."}, {"pmid": "23557023", "type": "DERIVED", "citation": "Zhong N, Lin J, Mehta P, Ngamjanyaporn P, Wu TC, Yunus F. Real-life effectiveness of budesonide/formoterol maintenance and reliever therapy in asthma patients across Asia: SMARTASIA study. BMC Pulm Med. 2013 Apr 4;13:22. doi: 10.1186/1471-2466-13-22."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study consisted of an initial screening visit followed by a 2-week run-in period before a 12-week treatment with investigational drug.", "recruitmentDetails": "A total of 1022 asthma patients were enrolled at 51 sites in 5 Asian countries: China (21 sites), India (12 sites), Indonesia (3 sites), Thailand (6 sites) and Taiwan (9 sites) during the period July 2009 to August 2010. Of the 1022 enrolled, 862 participants entered into a 12-week treatment with the investigational drug.", "groups": [{"id": "FG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "1022 participants were enrolled. There were 160 screen failures, 862 proceeded to treatment period.", "numSubjects": "862"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "862 participants entered into the 12-week treatment,66 discontinued, 796 completed the treatment.", "numSubjects": "796"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "66"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "15"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "23"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "13"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "Incorrect enrolment", "reasons": [{"groupId": "FG000", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "862"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"title": "All Participants", "categories": [{"measurements": [{"groupId": "BG000", "value": "13.7", "spread": "44.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "455"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "407"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Asthma Control Questionnaire (ACQ(5)) Score From Baseline at a Regional Level", "description": "Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12).", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "841"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.58", "spread": "-0.64", "lowerLimit": "-0.64", "upperLimit": "-0.51"}]}]}]}, {"type": "SECONDARY", "title": "Change in ACQ(5) Score From Baseline at Country Level (China)", "description": "Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12).", "populationDescription": "This outcome measure is reported at individual country level only, and therefore the number of patients analyzed are less than reported in participant flow, which captures the total patients in the region.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "386"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.58", "spread": "-0.67", "lowerLimit": "-0.67", "upperLimit": "-0.49"}]}]}]}, {"type": "SECONDARY", "title": "Change in Overall ACQ(5) Score From Baseline at Country Level (India)", "description": "Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12).", "populationDescription": "This outcome measure is reported at individual country level only, and therefore the number of patients analyzed are less than reported in participant flow, which captures the total patients in the region.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.74", "spread": "-0.92", "lowerLimit": "-0.92", "upperLimit": "-0.57"}]}]}]}, {"type": "SECONDARY", "title": "Change in Overall ACQ(5) Score From Baseline at Country Level (Indonesia)", "description": "Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12).", "populationDescription": "This outcome measure is reported at individual country level only, and therefore the number of patients analyzed are less than reported in participant flow, which captures the total patients in the region.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.18", "spread": "-1.40", "lowerLimit": "-1.40", "upperLimit": "-0.95"}]}]}]}, {"type": "SECONDARY", "title": "Change in Overall ACQ(5) Score From Baseline at Country Level (Taiwan)", "description": "Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12).", "populationDescription": "This outcome measure is reported at individual country level only, and therefore the number of patients analyzed are less than reported in participant flow, which captures the total patients in the region.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.22", "spread": "-0.38", "lowerLimit": "-0.38", "upperLimit": "-0.06"}]}]}]}, {"type": "SECONDARY", "title": "Change in Overall ACQ(5) Score From Baseline at Country Level (Thailand)", "description": "Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12).", "populationDescription": "This outcome measure is reported at individual country level only, and therefore the number of patients analyzed are less than reported in participant flow, which captures the total patients in the region.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.36", "spread": "-0.48", "lowerLimit": "-0.48", "upperLimit": "-0.23"}]}]}]}, {"type": "SECONDARY", "title": "Change in Asthma Quality of Life Questionnaire, Standardized Version (AQLQ (S)) Overall Scores From Baseline", "description": "Participants' QOL were scored on a scale of decreasing QOL impairment from 1 to 7, in which 1 = maximum impairment. The change in overall mean AQLQ(S) score from baseline were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12)", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "842"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.70", "spread": "0.64", "lowerLimit": "0.64", "upperLimit": "0.76"}]}]}]}, {"type": "SECONDARY", "title": "Change in AQLQ (S) Domain (Symptom) Scores From Baseline", "description": "Participants' QOL were scored on a scale of decreasing QOL impairment from 1 to 7, in which 1 = maximum impairment. The change in overall mean AQLQ(S) symptom score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12).", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "842"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.77", "spread": "0.70", "lowerLimit": "0.70", "upperLimit": "0.84"}]}]}]}, {"type": "SECONDARY", "title": "Change in AQLQ (S) Domain (Activity Limitation) Scores From Baseline", "description": "Participants' QOL were scored on a scale of decreasing QOL impairment from 1 to 7, in which 1 = maximum impairment. The change in overall mean AQLQ(S) symptom score from baseline were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12)", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "842"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.59", "spread": "0.53", "lowerLimit": "0.53", "upperLimit": "0.65"}]}]}]}, {"type": "SECONDARY", "title": "Change in AQLQ (S) Domain (Emotion Function) Scores From Baseline", "description": "Participants' emotional functions were scored on a scale of decreasing impairment to emotional function from 1 to 7, in which 1 = maximum impairment. The change in overall mean AQLQ(S) emotion function score were calculated as change from baseline (Week 0) to the treatment period (mean of the scores at Week 4, Week 8, Week 12)", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "842"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.77", "spread": "0.70", "lowerLimit": "0.70", "upperLimit": "0.84"}]}]}]}, {"type": "SECONDARY", "title": "Change in AQLQ (S) Domain (Environmental Stimuli) Scores From Baseline", "description": "Participants ' responses to environmental stimuli were scored on a scale of decreasing response to environmental stimuli from 1 to 7, in which 1 = maximum response. The change in overall mean AQLQ(S) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12)", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "842"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.67", "spread": "0.60", "lowerLimit": "0.60", "upperLimit": "0.74"}]}]}]}, {"type": "SECONDARY", "title": "Study Medication Use (Maintenance and Reliever) in Diary Cards - Change in As-needed Day-time Reliever Medication From run-in Period", "description": "Change in the number of as-needed day-time inhalations of medication, defined as the difference in mean value of all available data obtained during treatment period and mean value in run-in period.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Number of inhalations", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "841"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.30", "spread": "-0.36", "lowerLimit": "-0.36", "upperLimit": "-0.23"}]}]}]}, {"type": "SECONDARY", "title": "Study Medication Use (Maintenance and Reliever) in Diary Cards - Change in As-needed Night-time Reliever Medication From run-in Period", "description": "Change in the number of as-needed night-time inhalations of medication, calculated as difference in mean value of all available data obtained during treatment period and mean value in run-in period.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Number of inhalations", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "852"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.30", "spread": "-0.35", "lowerLimit": "-0.35", "upperLimit": "-0.24"}]}]}]}, {"type": "SECONDARY", "title": "Study Medication Use (Maintenance and Reliever) in Diary Cards - Total Number of Inhalations of Symbicort\u00ae 160\u00b5g/4.5\u00b5g Per Day During Treatment Period", "description": "Total number of inhalations of Symbicort\u00ae 160\u00b5g/4.5\u00b5g per day during treatment period, defined as the sum of maintenance medication and as-needed medication during night and day time", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Number of inhalations", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "858"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.51", "spread": "0.93"}]}]}]}, {"type": "SECONDARY", "title": "Study Medication Use (Maintenance and Reliever) in Diary Cards - Percentage of Days During Treatment Period Participants Used \u2265 3 Inhalations of Symbicort\u00ae 160\u00b5g/4.5\u00b5g in a Day", "description": "The mean percentage of days during treatment period participants used \u2265 3 inhalations of Symbicort\u00ae 160\u00b5g/4.5\u00b5g in a day", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of days", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "858"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "28.25", "spread": "33.03"}]}]}]}, {"type": "SECONDARY", "title": "Study Medication Use (Maintenance and Reliever) in Diary Cards - Percentage of Days During Treatment Period Participants Used \u2265 5 Inhalations of of Symbicort\u00ae 160\u00b5g/4.5\u00b5g in a Day", "description": "The mean percentage of days during treatment period participants used \u2265 5 inhalations of Symbicort\u00ae 160\u00b5g/4.5\u00b5g in a day", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of days", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "858"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.21", "spread": "16.17"}]}]}]}, {"type": "SECONDARY", "title": "Study Medication Use (Maintenance and Reliever) in Diary Cards - Percentage of Days During Treatment Period Participants Used \u2265 9 Inhalations of Symbicort\u00ae 160\u00b5g/4.5\u00b5g in a Day", "description": "The mean percentage of days during treatment period participants used \u2265 9 inhalations of Symbicort\u00ae 160\u00b5g/4.5\u00b5g in a day", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-08", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of days", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "858"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.19", "spread": "1.92"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Symbicort Turbuhaler", "description": "160/4.5 \u00b5g delivered dose", "seriousNumAffected": 12, "seriousNumAtRisk": 862, "otherNumAffected": 0, "otherNumAtRisk": 862}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 862}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 862}]}, {"term": "Cerebral Infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 862}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 862}]}, {"term": "Nasal Polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 862}]}, {"term": "Post procedural haemorrhage", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 862}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 862}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 862}]}, {"term": "Renal Cysts", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 862}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 862}]}, {"term": "Spinal Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 862}]}, {"term": "Ileus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 862}]}, {"term": "Breast Cancer", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 862}]}, {"term": "Atrioventricular block complete", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 862}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The design of the study does not allow for any conclusion regarding the effect of Symbicort SMART, it being a within-group comparison"}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com", "phone": "+44 1625 518062", "phoneExt": "28062"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["New Zealand"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}, {"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}